Event Brief
Dec 4, 2025 at 5:02 PM ET
Compass Pathways Eyes FDA Approval for Psilocybin Drug
By The BriefBrief
Compass Pathways is in final studies for psilocybin to treat depression, aiming for FDA approval.
WHO: Compass Pathways
WHAT: Final stage studies for psilocybin treatment
WHEN: Dec 3, 2025 at 7:00 PM ET
WHERE: United States
WHY: To treat patients with depression and explore commercial viability
How this brief is built: The BriefBrief correlates multiple sources into one evolving event brief, updated as new facts emerge.
Amazon faces months of repairs after drone strikes
Amazon
May 1, 2026 at 3:23 PM ET
Minnesota bans fake AI nudes; app makers face $500K
Minnesota
May 1, 2026 at 3:23 PM ET
Page 21432 of 21432
Same format. Every time.
Continue reading — sign in or create a free account with
